Patents by Inventor Ralf Huss

Ralf Huss has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230226222
    Abstract: A method for treating a subject having a medical condition associated with inflammation and/or an unwanted immune response without an alpha1-antitrypsin (AAT) deficiency, wherein the method comprises administering genetically modified mesenchymal stem cells to the subject, wherein said genetically modified mesenchymal stem cells comprise an exogenous nucleic acid comprising (i) an Alpha-1 antitrypsin (AAT) encoding region operably linked to (ii) a promoter or promoter/enhancer combination.
    Type: Application
    Filed: March 31, 2023
    Publication date: July 20, 2023
    Inventors: Christine GÜNTHER, Sabine GEIGER-SCHREDELSEKER, Felix HERMANN, Ralf HUSS, Daria Larissa FORSTER
  • Patent number: 11464806
    Abstract: A method of treating a tumor in a subject including administering a genetically modified mesenchymal stem cell (MSC), wherein the MSC includes one or more exogenous nucleic acid molecule(s), wherein the one or more exogenous nucleic acid molecule(s) includes one or more regions encoding two or more immune response-stimulating cytokines operably linked to one or more promoters or promoter/enhancer combinations, wherein the two or more immune response-stimulating cytokines include at least IL-7, and at least one of IL-12 or IL-21.
    Type: Grant
    Filed: January 28, 2020
    Date of Patent: October 11, 2022
    Assignee: JUNCTUCELL BIOMED MANUFACTURING GMBH
    Inventors: Christine Günther, Stefanos Theoharis, Felix Hermann, Ralf Huss
  • Publication number: 20200289577
    Abstract: A method of protecting a vascular endothelium from CD8+ cytotoxic T-lymphocyte mediated cytotoxic reactions in a subject who is about to receive or who has received an allogenic transplant and is at risk of developing or is afflicted with transplant-related complications, the method including administering to the subject human CD34-negative progenitor cells.
    Type: Application
    Filed: March 30, 2020
    Publication date: September 17, 2020
    Inventors: Günther EISSNER, Christine GUENTHER, Ralf HUSS
  • Publication number: 20200282078
    Abstract: A method for treating a subject having a medical conditions associated with inflammation and/or an unwanted immune response, and said subject does not have an alpha1-antitrypsin (AAT) deficiency, wherein the method includes administering genetically modified mesenchymal stem cells to the subject, wherein said genetically modified mesenchymal stem cells include an exogenous nucleic acid including (i) an Alpha-1 antitrypsin (AAT) encoding region operably linked to (ii) a promoter or promoter/enhancer combination.
    Type: Application
    Filed: February 25, 2020
    Publication date: September 10, 2020
    Inventors: Christine GÜNTHER, Sabine GEIGER-SCHREDELSEKER, Felix HERMANN, Ralf HUSS, Daria Larissa FORSTER
  • Publication number: 20200268802
    Abstract: A method of treating a tumor in a subject including administering a genetically modified mesenchymal stem cell (MSC), wherein the MSC includes one or more exogenous nucleic acid molecule(s), wherein the one or more exogenous nucleic acid molecule(s) includes one or more regions encoding two or more immune response-stimulating cytokines operably linked to one or more promoters or promoter/enhancer combinations, wherein the two or more immune response-stimulating cytokines include at least IL-7, and at least one of IL-12 or IL-21.
    Type: Application
    Filed: January 28, 2020
    Publication date: August 27, 2020
    Inventors: Christine Günther, Stefanos Theoharis, Felix Hermann, Ralf Huss
  • Publication number: 20180000969
    Abstract: Genetically modified mesenchymal stem cells can be used as a medicament in the treatment of medical conditions associated with inflammation and/or an unwanted immune response in subjects without an alpha1-antitrypsin (AAT) deficiency. The stem cells include an exogenous nucleic acid, which includes (i) an Alpha-1 antitrypsin (AAT) encoding region operably linked to (ii) a promoter or promoter/enhancer combination.
    Type: Application
    Filed: January 8, 2016
    Publication date: January 4, 2018
    Inventors: Christine GÜNTHER, Sabine GEIGER-SCHREDELSEKER, Felix HERMANN, Ralf HUSS, Daria Larissa FORSTER
  • Publication number: 20170239297
    Abstract: A genetically modified mesenchymal stem cell (MSC) and medical use thereof in the treatment of tumors, the MSC including one or more exogenous nucleic acid molecule(s), wherein the exogenous nucleic acid molecule(s) include a region encoding one or more immune response-stimulating or immune response-modulating cytokine(s) operably linked to a promoter or promoter/enhancer combination. The invention encompasses the use of the cells in modulating the tumor microenvironment in order to attract immune effector cells and facilitate their activation and/or adoption of a memory phenotype.
    Type: Application
    Filed: August 18, 2015
    Publication date: August 24, 2017
    Inventors: Christine Günther, Stefanos Theoharis, Felix Hermann, Ralf Huss
  • Publication number: 20160136207
    Abstract: This invention provides novel stem cell-based methods for treating a number of conditions. These methods employ CD34 stem cells, and have a tremendous advantage in that they do not require myeloablation in the subject being treated. The CD34 stem cells used in the instant methods can be genetically, modified or not, depending on the disorder treated.
    Type: Application
    Filed: May 8, 2015
    Publication date: May 19, 2016
    Applicant: APCETH GMBH & CO. KG
    Inventors: Ralf Huss, Peter J. Nelson, Matthias C. Raggi, Manfred J. Stangl
  • Patent number: 9255139
    Abstract: The present invention relates to fusion constructs of glycosylphosphatidylinositol (GPI)-anchored tissue inhibitors of metalloproteinases (TIMPs) and their use for the treatment of cancer and in regenerative medicine. By this approach, the GPI-anchored TIMP proteins are incorporated into the surface membrane of tumor cells and render tumor cells sensitive to FAS-induced apoptosis. Furthermore, the fusion constructs of the present invention are effective agents useful in wound healing applications. In one embodiment, the TIMP is linked to mucin followed by GPI in order to enhance surface presentation. The use of GPI to link TIMP renders the resulting fusion protein particularly useful as an anti-cancer agent for the treatment of cancer, and, in particular, any residual cancer following an incomplete surgical resection of primary tumors in an individual.
    Type: Grant
    Filed: September 20, 2006
    Date of Patent: February 9, 2016
    Inventors: Ralf Huss, Peter J. Nelson
  • Publication number: 20160008401
    Abstract: The present invention provides human CD34-negative progenitor cells for the use in protecting the vascular endothelium from immunologically mediated cytotoxic reactions of a subject at risk of, or afflicted with, vascular inflammatory disease. Also provided are a method for producing the human CD34-negative progenitor cells and a method for determining the ability of CD34-negative progenitor cells to protect the vascular endothelium from immunologically mediated cytotoxic reactions.
    Type: Application
    Filed: February 28, 2014
    Publication date: January 14, 2016
    Inventors: Günther Eissner, Christine Guenther, Ralf Huss
  • Publication number: 20150238541
    Abstract: This invention provides novel stem cell-based methods for treating a number of conditions. These methods employ CD34 stem cells, and have a tremendous advantage in that they do not require myeloablation in the subject being treated. The CD34 stem cells used in the instant methods can be genetically, modified or not, depending on the disorder treated.
    Type: Application
    Filed: May 8, 2015
    Publication date: August 27, 2015
    Inventors: Ralf Huss, Peter C. Nelson, Matthias C. Raggi, Manfred J. Stangl, SR.
  • Publication number: 20150238526
    Abstract: This invention provides novel stem cell-based methods for treating a number of conditions. These methods employ CD34 stem cells, and have a tremendous advantage in that they do not require myeloablation in the subject being treated. The CD34 stem cells used in the instant methods can be genetically, modified or not, depending on the disorder treated.
    Type: Application
    Filed: May 8, 2015
    Publication date: August 27, 2015
    Applicant: APCETH GMBH & CO. KG
    Inventors: Ralf Huss, Peter C. Nelson, Matthias C. Raggi, Manfred J. Stangl
  • Publication number: 20120208769
    Abstract: The present invention relates to chemokine-mucin fusions linked to glycosylphosphatidylinositol (GPI)-anchors and their use as anti-cancer adjuvants and as agents in tissue regeneration and suppression of vascular damage. GPI-linked chemokines are incorporated in the surface membrane of tumour cells and effect a recruitment of cytotoxic immune cells to the tumour site following injection in vivo. Leukocytes, cytotoxic T-cells and NK cells target the chemokine-GPI-anchored tumour cells and modulate cell-mediated lysis of the tumour cells. The efficiency of GPI-anchoring and modulation of immune cells can be further enhanced by linking the chemokine to a mucin domain followed by the GPI-anchor. The GPI-anchored chemokines, with or without mucin domain, are remarkably useful for the inhibition of tumour growth, tissue regeneration, and suppression of acute vascular damage to allografts.
    Type: Application
    Filed: November 30, 2006
    Publication date: August 16, 2012
    Inventors: Peter Jon Nelson, Ralf Huss, Hermann-Josef Grone
  • Publication number: 20110268714
    Abstract: This invention provides novel stem cell-based methods for treating a number of conditions. These methods employ CD34? stem cells, and have a tremendous advantage in that they do not require myeloablation in the subject being treated. The CD34? stem cells used in the instant methods can be genetically modified or not, depending on the disorder treated.
    Type: Application
    Filed: July 8, 2011
    Publication date: November 3, 2011
    Inventors: Ralf HUSS, Matthias C. Raggi, Manfred J. Stangl, Peter C. Nelson
  • Patent number: 7998472
    Abstract: This invention provides novel stem cell-based methods for treating a number of conditions. These methods employ CD34? stem cells, and have a tremendous advantage in that they do not require myeloablation in the subject being treated. The CD34? stem cells used in the instant methods can be genetically modified or not, depending on the disorder treated.
    Type: Grant
    Filed: May 20, 2008
    Date of Patent: August 16, 2011
    Assignee: Apceth GmbH & Co. KG
    Inventors: Ralf Huss, Matthias C Raggi, Manfred J Stangl, Peter C Nelson
  • Publication number: 20110105407
    Abstract: The present invention relates to fusion constructs of glycosylphosphatidylinositol (GPI)-anchored tissue inhibitors of metalloproteinases (TIMPs) and their use for the treatment of cancer and in regenerative medicine. By this approach, the GPI-anchored TIMP proteins are incorporated into the surface membrane of tumor cells and render tumor cells sensitive to FAS-induced apoptosis. Furthermore, the fusion constructs of the present invention are effective agents useful in wound healing applications. In one embodiment, the TIMP is linked to mucin followed by GPI in order to enhance surface presentation. The use of GPI to link TIMP renders the resulting fusion protein particularly useful as an anti-cancer agent for the treatment of cancer, and, in particular, any residual cancer following an incomplete surgical resection of primary tumors in an individual.
    Type: Application
    Filed: September 20, 2006
    Publication date: May 5, 2011
    Inventors: Ralf Huss, Peter Jon Nelson
  • Publication number: 20090041735
    Abstract: This invention provides novel stem cell-based methods for treating a number of conditions. These methods employ CD34? stem cells, and have a tremendous advantage in that they do not require myeloablation in the subject being treated. The CD34? stem cells used in the instant methods can be genetically modified or not, depending on the disorder treated.
    Type: Application
    Filed: May 20, 2008
    Publication date: February 12, 2009
    Applicant: Apceth GmbH & Co. KG
    Inventors: Ralf Huss, Matthias C. Raggi, Manfred J. Stangl, Peter C. Nelson
  • Patent number: 6361997
    Abstract: The invention relates to the use of genetically modified, very early haematopoietic and mesenchymal stem cells (negative for the expression of the surface molecule CD34) in the individual gene therapy of mono- or oligogenetic diseases or in cell therapy. Autologous CD34-negative adherently growing stem cell cultures from the peripheral blood of the patient are applied and efficiently tranfected or infected with genetic constructs. The gene products of these genes should substitute defective or absent proteins or factors in the patient organism in the long term. After expansion, the autologous stem cells can also be used for cell therapy (organ replacement therapy).
    Type: Grant
    Filed: February 24, 2001
    Date of Patent: March 26, 2002
    Inventor: Ralf Huss